SecBot SecBot
8-K ·Filed May 7, 2026

KOD

Kodiak Sciences Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001193125-26-211811
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Traders should focus on upcoming catalysts: DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 data. Cash runway into 2027 provides a buffer. No guidance change; stock likely to trade on pipeline news rather than financials.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$41.01
T+0 close · May 7, 2026 · via day close
Latest settled
+4.58%
T+60 · $42.89
Vs SPY
−0.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $41.01entry
  2. T+1 · 6mo ago −2.83%α −3.06% · $39.85
  3. T+5 · 6mo ago −5.63%α −7.10% · $38.70
  4. T+20 · 5mo ago −24.29%α −24.31% · $31.05
  5. T+60 · 3mo ago +4.58%α −0.26% · $42.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kodiak Sciences reported Q1 2026 net loss of $58.2M ($0.94/share) vs $57.5M ($1.09/share) in Q1 2025, essentially in line with consensus of $0.93. The pre-revenue biotech highlighted positive GLOW2 data and expects DAYBREAK (Sep 2026) and PEAK (Q4 2026) Phase 3 readouts. Cash of $169.5M is expected to fund operations into 2027.

Key Financial Metrics

EPS
−$0.94
est −$0.93 · -1.1%
Rating
in line

Key Facts

  • Net loss $58.2M, or $0.94 per share, vs $57.5M ($1.09) in Q1 2025
  • Cash and cash equivalents $169.5M, down from $209.9M at Dec 31, 2025
  • R&D expenses $48.5M vs $43.6M YoY, driven by increased clinical activities
  • Zenkuda BLA submission planned; DAYBREAK topline data expected Sep 2026
  • KSI-101 Phase 3 PEAK topline expected Q4 2026, PINNACLE Q2 2027
  • No revenue; company is pre-commercial

Financial Impact

Net loss per share $0.94 vs consensus $0.93, essentially in line. Cash burn ~$40M in the quarter.

net losscash positionR&D spend

Risk Factors

  • Potential delays or failures in Phase 3 trials (DAYBREAK, PEAK, PINNACLE)
  • Cash burn rate may require additional financing before readouts
  • BLA submission and approval risks for Zenkuda

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-211811
Document: kod-20260507.htm0001193125-26-211811
Document: 0001193125-26-211811-index-headers.html0001193125-26-211811
Document: 0001193125-26-211811-index.html0001193125-26-211811
Document: 0001193125-26-211811.txt0001193125-26-211811
8-K Data (Synthetic)0001193125-26-211811

Track record

13 reports on KOD

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $100.73 +4.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $100.73 +8.01% settles Dec 15
  3. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $111.19 Now $100.73 −9.41% settles Dec 14
  4. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $100.73 −5.95% settles Dec 8
  5. Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $100.73 −14.83% settles Nov 18
  6. Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
  7. Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
  8. Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $100.73 +12.02% ▼ −0.36% −0.32% vs SPY
  9. Aug 13, 202613w ago 8-K Neutral 4/10 No price data
  10. Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $100.73 +143.60% ▼ −19.85% −17.86% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (14h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026